Two calendars govern the same decision
Molina Healthcare determined in early February 2026 that its Medicare Advantage prescription drug product no longer fit where the company was heading. Investors learned about it on the fourth-quarter earnings call, and the determination was written into the annual report Molina filed with the Securities and Exchange Commission. The people holding those plans will learn about it from a letter that, under the CMS enrollment calendar, does not go out until early October.
Neither disclosure breaks a rule. Public companies tell investors about material decisions once the board makes them. Health plans tell members on a schedule CMS sets, and the non-renewal notice for coverage beginning January 1, 2027 is due by October 2. What the arrangement produces is not concealment but a staggered sequence. The market prices the decision in February. The member reorganizes a prescription list in October.
The distance between those two dates is the part of this story that outlives Molina. Every insurer trimming its Medicare footprint this year is running the same two clocks, and the gap between them is measured in months rather than days.
The exit finishes a retreat that started in thirteen states
The 2027 exit reads like a sudden reversal. The filings describe something closer to a final step. Molina's 2025 annual report records that the company exited the same product in thirteen states during 2025, and that the move was already reshaping the Medicare segment's revenue. What remains for 2027 is the balance of the national footprint.
The numbers in the filing are specific. Molina's Medicare Advantage prescription drug contracts covered approximately 117,000 members in 2025 and accounted for about $1,566 million, or a quarter of the Medicare segment's premium revenue. The company expects that enrollment to fall to roughly 80,000 during 2026 and 2026 premium revenue from the product to come in near $1 billion. Total Medicare enrollment is projected to decline about 12 percent to 230,000 members by year end.
The product being retired is the traditional, non-dual version. Molina is keeping its dual-eligible business, which it values at about $5 billion and which it continues to expand through new contracts in Idaho, Illinois, Massachusetts, Michigan and Ohio. The company's stated reason for the exit is that the traditional product does not fit a strategy built around members who qualify for both Medicare and Medicaid.
That is a coherent business position, and it is also a statement about which Medicare members are worth serving. Dual-eligible members bring two revenue streams and a different risk profile. A member who qualifies only for Medicare brings one. Molina is not the first insurer to make that calculation, and the filings are unusually direct about it.
What the members are holding
The product's name does a lot of work that the member may not have done. A Medicare Advantage prescription drug plan is not a standalone drug plan. It is a Medicare Advantage plan that bundles hospital, medical and drug coverage into a single card, and dropping it does not leave the member with a hole where drugs used to be. It ends the plan.
That distinction sets up the most common misunderstanding. Members sometimes treat the notice as a change in benefits inside a plan that will continue, the way an annual notice of change describes new copays. A non-renewal is a different document. It says the plan will not exist on January 1.
Members in Dual Eligible Special Needs Plans sit outside this exit. Their plans are a separate product line, and the company is investing in that line rather than leaving it. Molina has been explicit that the dual-eligible business is the part of Medicare it intends to keep.
The clock starts when the letter lands
The Medicare annual enrollment period runs from October 15 to December 7, and it is the window in which a member of an exiting plan locks in coverage for January 1. Medicare lists the enrollment periods and what each one permits on its plan enrollment page. A member who does nothing generally returns to Original Medicare on January 1, and returning to Original Medicare does not automatically produce drug coverage.
That is where the penalty lives. Medicare imposes a late enrollment penalty on anyone who goes 63 or more days in a row without prescription drug coverage that counts as creditable, and the penalty is permanent once assessed. It is calculated as one percent of the national base beneficiary premium for each full month without coverage. For 2026 the base premium is $38.99, so a member who goes a year without coverage pays roughly $4.68 a month on top of whatever plan they eventually join. Medicare explains the calculation in its guide to the penalty, and the penalty is charged against the base premium rather than the plan's own premium, so shopping for a cheaper plan does not reduce it.
Two other protections matter and both have edges. A plan termination normally triggers a special enrollment period, which gives a member a second window outside the fall period. Members who return to Original Medicare also get a federal guaranteed-issue right for Medigap coverage, which means an insurer cannot medically underwrite the policy or turn them down. That right is available only within a limited window after the coverage ends. Miss it, and in most states a Medigap application later can be denied or priced up for pre-existing conditions.
The Medicare Advantage open enrollment period, which runs from January 1 to March 31, looks like a safety net and is a partial one. It lets a member already enrolled in a Medicare Advantage plan switch to another Medicare Advantage plan or drop back to Original Medicare. It does not reopen the Part D clock, and a member who spends January without drug coverage is already accumulating months toward the 63-day threshold that triggers the penalty. The fall window is the one that matters, and the January window is a correction for members who used it badly.
Members with low incomes have a separate path. Those enrolled in Extra Help, the program that subsidizes Part D premiums and copays, are not charged the late enrollment penalty while they receive it, and the penalty can be eliminated outright rather than merely paused. Some beneficiaries in that group are moved into a benchmark plan automatically when their plan ends, which means the letter they receive may describe a change they do not have to act on. The distinction between a member who must choose and a member who is being moved is not always clear in the notice itself, which is one reason the plan and the state's Senior Health Insurance Information Program are both worth a call.
The practical shape of the next eight weeks is small. Run the drug list through the plan finder on Medicare.gov. Call the plan and the prescriber to confirm that each drug is on the formulary and that the pharmacy is in network, because the aggregator data lags. Keep the non-renewal letter, since it documents an involuntary loss of coverage and is the document that supports both the special enrollment period and the Medigap right.
Molina is filing alongside an industry
The exit lands in a year when the Medicare Advantage market is contracting in a way it has not for most of its existence. Analysts tracking the filings put the total number of members affected by 2027 plan exits above one million. Humana is leaving plans covering roughly 600,000 members. Providence and Presbyterian Healthcare Services are winding down most of their Medicare Advantage offerings. UnitedHealthcare is weighing an exit from dozens of counties while expecting to end 2026 with up to 1.1 million fewer Medicare Advantage members than it started with.
A study by Johns Hopkins researchers published in the Journal of the American Medical Association found that about ten percent of Medicare Advantage enrollees, some 2.9 million people, had to change plans for 2026 because their insurer left the market. The comparable figure averaged around one percent a year between 2018 and 2024. Rural members were disrupted at roughly twice the urban rate, and in a dozen states more than a fifth of enrollees lost the plan they had.
The exits are not distributed evenly across the plans a company sells. Star ratings, which CMS publishes each fall and which determine whether a plan earns a quality bonus, have become the sorting mechanism. Humana's 2027 exits concentrate on plans rated 3.5 stars or lower, the tier where the bonus stops. A plan that scores below the threshold loses a subsidy that flows into benefits, which changes the arithmetic on whether keeping it is worthwhile.
The backdrop is payment. CMS finalized an average increase of 2.48 percent in Medicare Advantage payments for 2027, worth about $13 billion, after proposing an increase of 0.09 percent in January and drawing more than 40,000 comments in response. The agency also declined to adopt the risk adjustment model it had proposed and finalized a change that excludes diagnoses from unlinked chart review records, so a diagnosis counts toward payment only when it connects to an actual patient encounter. Chris Klomp, the director of Medicare, framed the final notice as a deliberate turn rather than a squeeze, saying that "the days of unlimited increases in rate must end." The line is worth taking at face value. It describes a payment trajectory the agency intends to hold, which means the cost pressure insurers cite when they file exits is a condition of the program rather than a temporary rough patch.
Plan exits and rate pressure are related without being identical, and the relationship is not mechanical. Insurers cite medical cost trends, star ratings that determine bonus payments, and rate updates that have trailed cost growth. A plan can be profitable and still be dropped because a company would rather deploy the capital somewhere with a better return. Molina's own filing describes a strategic choice, not a distressed one.
What a replacement decision has to answer
The four questions worth answering are narrower than a plan comparison site suggests. Each current prescription, its tier on the new formulary, and whether it needs prior authorization. The doctors, hospital and preferred pharmacy, checked against the network rather than assumed. The medical out-of-pocket maximum, which is the number that caps a bad year. And whether returning to Original Medicare opens a Medigap guaranteed-issue window and when that window closes.
Premium is the least informative of the available numbers. A plan with a low monthly premium and a restrictive formulary can cost more across a year than a plan with a higher premium and broader coverage, and the difference lands on the member at the pharmacy counter rather than in the marketing material.
The larger point is structural. Medicare drug coverage now moves on two calendars that were designed for different audiences and were never meant to be coordinated. One governs what shareholders learn and when. The other governs what a member learns and when. Molina's exit is a clean example because the company disclosed early, in writing, and on the record. The eight months between the earnings call and the letter is not evidence that anything was hidden. It is what the system produces when it is working as designed, which is the harder fact to sit with.
Primary sources
- Molina Healthcare 2025 Form 10-K for the MAPD exit determination, the member and revenue figures, the thirteen-state 2025 exit, the dual-eligible strategy, and the enrollment projections.
- Medicare.gov for the annual enrollment period dates, the consequences of taking no action, and the Part D late enrollment penalty calculation and 2026 base beneficiary premium.
- CMS for the finalized 2027 Medicare Advantage rate announcement, the 2.48 percent average increase, the risk adjustment model decision, and the director of Medicare's remarks.
- Becker's Payer Issues, Healthcare Dive and Modern Healthcare for the 2027 insurer exits, the affected member counts, and the Humana and UnitedHealthcare figures.
- JAMA study by Johns Hopkins researchers for the 2026 forced-disenrollment rate and the rural and urban comparison.